L9918

Anti-LRRK2 (C-terminal region) antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution

• Synonym(s): Anti-AURA17, Anti-Dardarin, Anti-Leucine-rich repeat protein kinase 2, Anti-PARK8, Anti-RIPK7, Anti-ROCO2
• UNSPSC Code: 12352203
• NACRES: NA.44

Properties

• biological source: rabbit
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: antigen ~240 kDa
• species reactivity: rat, mouse, human
• enhanced validation: recombinant expression; Learn more about Antibody Enhanced Validation
• concentration: ~1.0 mg/mL
• technique(s): western blot: 2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using rat and mouse brain extracts (S2 fraction)
• UniProt accession no.: Q5S007
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... LRRK2(120892) ; mouse ... Lrrk2(66725) ; rat ... Lrrk2(300160)

Description

General description

Leucine-rich repeat protein kinase 2 (LRRK2) comprises multiple domains, including a leucine-rich repeat (LRR) domain, a Roc (Ras of complex proteins) GTPase domain followed by a C-terminal of ROC (COR) domain, a Ser/Thr kinase domain and a C-terminal Trp-Asp-40 (WD40) domain. The N-terminal region (?900 amino acids) contains ankyrin (ANK) repeats. The LRRK2 homologue LRRK1 shares domain structure similarity with LRRK2.

Specificity

Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans.

Application

Anti-LRRK2 (C-terminal region) antibody is suitable for use in western blot (2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using S2 fractions of rat and mouse brain extracts).

Biochem/physiol Actions

LRRK2 is a μLtimeric kinase that also functions as a GTPase. LRRK2 activates a calcium/calmodulin-dependent protein kinase kinase (CaMKK)-β/AMPK signaling pathway and subsequently mediates autophagy. Genetic alterations in LRRK2 cause late-onset Parkinson′s disease . Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans. Staining of the LRRK2 band by immunoblotting is specifically inhibited by the LRRK2 immunizing peptide.

LRRK2 mRNA is expressed throughout the brain predominantly within regions of the basal ganglia that are associated with Parkinson′s disease. The presence of multiple protein interaction domains suggests that in addition to its kinase and GTPase activities, LRRK2 may serve as a scaffold protein for the assembly of multiprotein signaling complex. R1441C mutation has been shown to disrupt GTPase activity. G2019S and R1441C, both associated with increased kinase activity.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 10 - Combustible liquids
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves